Macular degeneration is a type of progressive eye disease that causes the loss of central field of vision. In the case of dry age-related macular degeneration, the deterioration of the retina occurs. Furthermore, in case of wet macular degeneration, the growth of leaky blood vessels occur under the retina.
The function of the macular area (centre of the retina) is similar to that of a digital processor or film in a camera. In case of cameras, if there is any damage to the digital processor or film it results in blurry pictures. Likewise, in human eye, if the macular area is affected it leads to a significant vision loss that affects daily activities to a certain extent. As per a survery conducted by the World Health Organization (WHO), age-related macular degeneration is ranked amongst the 3rd global cause of visual impairment with the prevalence rate of 8.7% of the total blindness occuring globally.
are the factors boosting the market growth. The key emerging trends include numerous drugs under the pipeline for AMD, novel emerging techniques for the treatment of wet AMD drugs, increasing research grants, and awareness for wet AMD.
Get a sample report at https://www.marketresearchfuture.com/sample_request/5736 .
Some of the key players in the global age-related macular degeneration market are Novartis International AG (Switzerland),Alcon Vision Care (U.S.), Bayer AG (Germany), Acucela Inc. (U.S.), Neurotech Pharmaceuticals Inc. (U.S.), Ophthotech Corporation (U.S.), GlaxoSmithKline Plc (U.S.), Alimera sciences Inc. (U.S.), StemCell Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron Pharmaceutical Inc. (U.S.), Allergan Plc (Ireland), Adverum Biotechnologies Inc. (U.S.), Gilead Sciences Inc. (U.S.), Iconic Therapeutics Inc. (U.S.), Lpath Inc. (U.S.), OHR Pharmaceutical Inc. (U.S.), Bausch + Lomb (U.S.), Opthea Limited (Canada), PanOptica, Inc. (U.S.), Pfizer Inc. (U.S.), Neurotech Pharmaceuticals, Inc. (U.S.), Promedior, Inc. (U.S.), QLT Inc. (Canada), Quark (U.S.), Resolvyx Pharmaceuticals Inc. (U.S.), RXi Pharmaceuticals Inc. (U.S.), Sagent Pharmaceuticals, Inc. (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Sanwa Kagaku Kenkyusho (Japan), and others.
The global age-related macular degeneration market consists of four regions such as the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global age-related macular degeneration market owing to the growing occurrence of age-related macular degeneration in the South American region, eye disorders among the adolescents, and the rising awareness about its long-term effects. According to the American Macular Degeneration Foundation, around 85 to 90% of the cases of macular degeneration are considered as dry AMD, whereas 10 to 15% are categorized under wet AMD.
The European region accounted for the second largest market owing to factors such as the rising geriatric population and the increasing prevalence of eye disorders such as stargardt disease, different types of macular degenerations, and diabetic retinopathy. The Asia Pacific region is anticipated to witness a fast growth during the forecast period for the global age-related macular degeneration market.
Browse Complete Report at https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736 .
The global age-related macular degeneration market is segmented by type, drug, route of administration, treatment, and end-user.
On the basis of type, the global age-related macular degeneration market is segmented into dry age-related macular degeneration and wet age-related macular degeneration
On the basis of drug, the global age-related macular degeneration market is segmented into Eylea, Visudyne, Lucentis, Avastin, and others.
On the basis of route of administration, the global age-related macular degeneration market is segmented into intravenous, intravitreal, and others.
On the basis of treatment, the global age-related macular degeneration market is segmented into medications, devices, surgery, and others. The medication segment is further classified into anti-VEGF drugs, blood vessel growth inhibitors, vitamins, dietary supplements, and others. The devices segment is classified into corrective lens, glasses, contact lenses, and others.
Company Name: Market Research Future
Contact Person: Akash Anand
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –